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Background: Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in
promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore,
blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment.
Methods: To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we
investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma
cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine
(BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and
eosin, and Ki-67 and CD34 markers were stained, respectively.
Results: Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70,
P > 0.05) in treated SW-48 cells with SD-208 compared to controls.
Conclusion: Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human
colorectal cancer model at least using SW-48 cells.
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Colorectal cancer (CRC) is the second leading cause of can-
cer death among adults, making it as an excellent and desir-
able area for clinicians and researchers to study [1,2]. It has
been also found that a large proportion of cancers such as
CRC display inactivation of the growth factors specially
transforming growth factor-β (TGF-β) pathway but they
are characterized by increasing the factor production. In
man, three isoforms of TGF-β including TGF-β1, TGF-β2
and TGF-β3 have been well characterized [3,4]. The hom-
ology searching has revealed that these proteins share up to
75% amino acid sequences. In spite of the fact that they
have demonstrated comparable signaling activities, they are* Correspondence: mheidari@sina.tums.ac.ir
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unless otherwise stated.differentially expressed in cell lineages and tissues. It has
been also frequently reported that TGF-β is the most effect-
ive growth inhibitor for normal epithelial, hematopoietic
and immune cells. Studies showed that TGF-β acts as a
double-edged sword in the biological processes [3-6]. In
addition, it plays important roles in primary tumor progres-
sion and in promoting metastasis and has become an at-
tractive target for therapy [5-7]. TGF-β exerts its effects by
acting on two types of transmembrane receptors: type I
(TGβRI) and type II (TGβRII). These receptors are involved
in signal transduction, triggers through interaction of the
TGF-β with TGβRII. Once TGF-β binds to TGβRII leads to
the recruitment, phosphosphorylation, and activation of
TGβRI. Activation of the TGβRI invokes several TGF-β sig-
naling pathway targets and downstream genes [7,8]. Based
on the literature, targeting of TGF-β signaling could be
a valuable tool to treatment of human cancers such as
CRC, glioblastoma and breast cancer [6-10]. Several studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Continuous culture of SW-48 cells and treatment with
SD-208. The cells were grown as monolayer epithelial-like
morphology. SW-48 cells after treatment by DMSO alone as control
(A), SD-208 concentrations 0.5 μM (B), 1 μM (C) and 2 μM (D).
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kinase inhibitors such as SD-208 could be a powerful ap-
proach for the treatment of various cancers. SD-208 is a
small-molecule kinase inhibitor that bind to the ATP-
binding site of the TGβRI kinase and maintains the enzyme
in its inactive configuration [11-13]. Despite advances in
our understanding of the molecular and genetic basis of
CRC, effective treatment of the disease remains a clinical
challenge. As pointed out, TGF-β promotes cell prolifera-
tion, development, invasion and metastasis in several types
of tumors. It is thought that TGβRI inhibitor may have a
therapeutic benefit in CRC; therefore, pharmacological
blockade of the TGF-β signaling pathway has been pro-
posed as a benefit strategy for CRC therapy. In the current
study, SW-48, colon adenocarcinoma cell line was treated
with different doses of SD-208, an anti-cancer agent. We
evaluated the effects of SD-208 on cell proliferation and
differentiation in vitro and in vivo.
Methods
Cell culture
Human colorectal adenocarcinoma cell line with patho-
logic differentiation grade of the original tumors IV, SW-
48, was obtained from National Cell Bank of Iran (NCBI)
affiliated to Pasteur Institute (Tehran, Iran). The cell line
was grown in RPMI-1640 medium (Gibco; Germany) con-
taining 25 mM D-glucose, 4 mM L-glutamine and 1 mM
sodium pyruvate and supplemented with 5% (v/v) heat
inactivated fetal bovine serum (FBS) (Gibco; Germany),
2 mM glutamax (Gibco; Germany), 100 units/ml penicil-
lin, 100 μg/ml streptomycin and 250 ng/ml amphoterycin
(Gibco; Germany) in culture flask 25 cm2 (SPL Life
Sciences; South Korea). The cells were kept at 37°C in a hu-
midified 95% atmosphere, 5% CO2 atmosphere incubator
designated as culture at a steady-state condition. Cell viabil-
ity was assessed using trypan blue exclusion test and rou-
tinely found to all flasks contain more than 95% viable cells.
Chemical description and biological activity TGβRI kinase
inhibitor, SD-208
SD-208 (Sigma Aldrich; Belgium) is a selective and orally
active pyridopyrimidine type TGβRI kinase inhibitor with
an IC50 of approximately 35 nmol/L against TβRI kinase
activity in vitro. The drug was dissolved in 100% dimethyl-
sulfoxide (DMSO; Sigma Aldrich; Belgium) and prepared
as stock solutions of 5 mM in DMSO and kept at −20°C
until use.
MTT assay
The in vitro growth inhibitory effect of SD-208 was
measured by the MTT assay (Roche Applied Science;
Germany). This assay is dependent on the ability of vi-
able cells to reduce a yellow tetrazolium salt (MTT)
metabolically to a purple formazan product. This reactiontakes place when the cell is viable and mitochondrial re-
ductase enzymes are active. Briefly, monolayer cultures
were trypsinized in exponential growth phase, and viable
cell counts were assessed using trypan blue exclusion.
Then, cells were seeded in 96-well flat-bottom microtitra-
tion plates (SPL Life Sciences; South Korea) at a density of
5 × 104 cells/well (200 μL media/well). After 24 h, once
the cells reached ~85% confluence they were treated with
different concentrations of SD-208 (0.5 μM, 1 μM and 2
μM). Following 24 h drug exposure, for the recovery
period, the cells were washed two times with fresh and
free-FBS medium and the culture continued (Figure 1).
Subsequently, fresh medium containing FBS was replaced
for removal of efflux and unbound drug. In all in vitro ex-
periments, control cells were incubated with dimethylsulf-
oxide (DMSO) alone (with the final concentration 0.2%).
Complete medium was replaced with 100 μl MTT after 48
h incubations. The cells were incubated for 3 h at 37°C
then MTT was removed, and 300 μl DMSO were added
to each well. Finally, the optical densitometry was mea-
sured at a wavelength of 490 nm with background sub-
traction at 630 nm using a spectrophotometric microplate
reader (BioTek Elx 808). The growth inhibition rate was
calculated using the following formula:
Growth inhibition rate %ð Þ ¼ 1− ODdrug exposure=ODcontrol
 
 100
BrdU assay
The BrdU assay was performed using BrdU ELISA kit ac-
cording to the manufacturer’s instructions (Roche Applied
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tion base on the measurement of BrdU incorporation dur-
ing DNA synthesis. Briefly, the SW-48 cells were seeded in
96-well flat-bottom microtitration plates at a density of 5 ×
104 cells/well (100 μl media/well). After 24 h at 37°C, the
cells were treated with different concentrations of SD-208
(0.5 μM, 1 μM and 2 μM). Every well, except for the back-
ground controls, received 10 μl marker solution (1:100 di-
lution with a sterile medium) and the cells were further
incubated for 5 h at 37°C under 5% CO2. Removal of the
medium from the wells was followed by incubation of the
cells in 200 μl FixDenat for 30 min. The FixDenat was re-
moved, and the cells were further incubated for 75 min
with the antibody solution. The cells were then washed
three times with 200 μl washing buffer (1:10 dilution) and
then incubated in 100 μl substrate solution (tetramethyl-
benzidine) for 15 min. Absorbance was measured at a
wavelength of 490 nm using a spectrophotometric micro-
plate reader (BioTek Elx 808). Cells from the same popula-
tion and treatment that were not BrdU-labeled were used
as the background controls. The cell proliferation was cal-
culated using the following formula:
Cell proliferation %ð Þ ¼ ODdrug exposure=ODcontrol
 
 100
Animal model implanted with adenocarcinoma cell line
(SW-48) and treatment protocol
6–week–old female athymic C56BL/6 nude mice (n = 8
per group) were obtained from Omid Institute for
Advanced Biomodels (Tehran, Iran). Animals were kept
under optimized hygienic conditions in an individually
ventilated cage system. The mice were fed with autoclaved
commercial diet and water ad libitum. All animal experi-
ments were carried out according to the Tehran University
of Medical Sciences, Ethical Committee Acts and were ap-
proved by the TUMS Ethical Committee. In order to es-
tablish the xenograft model of SW-48 cell line, the cells
were cultured in RPMI 1640 containing 10 percent FBS in
75 cm2 cell culture flasks. The cells were trypsinized and
harvested. After washing, totally 5 × 106 cells were resus-
pended and inoculated subcutaneously at a 200 μl volume
of serum–free medium into the flank of the animals.
Tumor growth was measured twice a week. The volume
of tumors was calculated by standard formula (Length ×
width2 × 0.52) and growth curve was drawn (Tomayko,
1989). Xenograft tumors were allowed to reach a size of
100 mm3. Then, the animals were randomly divided into
two groups of 8 to receive either SD-208 (50 mg/kg/d) or
vehicle orally for three weeks. Control animals were re-
ceived daily drug-free and DMSO-containing deionized
water (vehicle). At the end of the treatment period, mice
were killed by CO2 inhalation and obtained tumors afterisolating from animal were fixed in 10% buffered formalin
and were subjected to histopathological staining.Histopathological diagnosis and immunohistochemistry
Hematoxylin and eosin (H&E) staining for SW-48 tumor
confirmation and immunohistochemistry (IHC) staining
for Ki-67 and CD34 markers were done. Then, five sect-
ions at routine thickness (5 μm) were prepared from the
formalin-fixed paraffin-embedded tissue blocks and floated
onto charged glass slides (Super-Frost Plus, Fisher Scientific).
The slides then were dried overnight at 60°C. For the
revision of the histopathological diagnosis and confirm-
ation of developed the SW-48 cell-derived tumors, two
hemotoxylin and eosin stained sections were obtained from
tissue blocks. Immunohistochemistry carried out for the
evaluation of SD-208 effects on proliferation and angiogen-
esis (Ki-67 and CD34 marker, respectively) in the tumor
xenografts. For this, three sections were deparaffinized and
hydrated using graded concentrations of ethanol to deion-
ized water from each block. These sections were stained
immunohistochemically using three steps-indirect strepta-
vidin method for Monoclonal Mouse Anti-Human Ki-67
Antigen (MIB-1), clone M 7240 (Dako; Denmark) and
Monoclonal Mouse Anti-Human CD34, clone QBEnd-10
(Dako; Denmark). Negative controls were obtained by
omitting the primary antibody for aforementioned markers
under identical test condition. Sections from a lymph node
with follicular lymphoid hyperplasia known to be immuno-
reactive for Ki-67 and CD34 were used as a positive control
(as recommended by the manufacturer).Statistical analysis
Statistical analysis was performed, and statistical signifi-
cance of differences between data was evaluated by inde-
pendent sample Student’s t-test for tumor markers (Ki-67
and CD34) and one-way analysis of variance (ANOVA)
followed by Tukey’s post tests for multiple comparisons of
differences between treatment groups. Data were expressed
as mean ± SEM (the standard error of the mean). P values
less than 0.05 were considered to indicate statistically sig-
nificant differences between data sets.Results
In vitro effects of SD-208 on SW-48 cell line
In order to examine the growth inhibitory effect of SD-
208 on CRC, the SW-48 cell line was cultured with dif-
ferent SD-208 concentrations (0.5 μM, 1 μM and 2 μM)
for 48 h (Figure 1). As shown in Table 1, evaluation of
in vitro growth inhibition by MTT (Figure 2A) and BrdU
assays (Figure 2B) revealed no significant changes in
treated versus untreated cells (P > 0.05).
Table 1 Effects of SD-208 on growth of SW-48 cell line
MTT assay
Inhibition rate (IR)% P value OD value
(mean ± SEM)
Concentration of
SD-208 (μM)
2.06 ± 0.085 Untreated
2.36 0.69 1.64 ± 0.098 Control (DMSO)
2.57 0.63 1.61 ± 0.093 0.5
3.4 0.6 1.54 ± 0.099 1
3.64 0.57 1.51 ± 0.098 2
BrdU assay
2.14 ± 0.079 Untreated
2.24 0.68 1.73 ± 0.081 Control (DMSO)
2.32 0.64 1.71 ± 0.087 0.5
2.6 0.63 1.69 ± 0.097 1
3.2 0.59 1.62 ± 0.098 2
Akbari et al. DARU Journal of Pharmaceutical Sciences 2014, 22:47 Page 4 of 7
http://www.darujps.com/content/22/1/47Colon adenocarcinoma model
To determine the potential toxicity effects of SD-208,
the appropriate numbers of SW-48 cells were injected
into nude mice. Subsequently, animals were treated with
or without SD-208 (as described in the Methods sec-
tion). Following SD-208 treatment, we could not observe
any changes in animal behavior, body weight and life-
span. These data suggest that SD-208 lacks toxic effects
on mice bearing SW-48 tumor (data not shown).Figure 2 Effect of SD-208 on the cell growth and proliferation of the SW
proliferation was examined by MTT and BrdU assays as described in methods
with controls (untreated and treated with DMSO). B: BrdU assay of SW-48 cell
treated with DMSO). All data are reported as the percentage change in comp
proliferation. Analysis of one-way ANOVA was used to compare the cell prolif
P value < 0.05 was regarded as statistically significant. Results are expressed asTen days after the subcutaneous inoculation, all 24
nude mice with an observed tumor growth survived with
a balanced diet (Figure 3). Based on the standards of
cancer-bearing models, 24 mice were selected for further
experiments. The mice were sacrificed, and their tumor
tissues were excised for pathological examinations.
The H&E staining demonstrates marked cellularity with
profound hyperchromatism and pleomorphism (Figure 4).
Pleomorphic malignant epithelial cells with the clearly nu-
cleolus were visible. In tumor cells, the ratio of nucleus to
the cytoplasm was 1/1. Also, high mitotic index and atyp-
ical areas were observed in both samples (treated versus
controls). The pattern of adenocarcinoma was identical
with the human origin in which the cancerous cells were
poorly differentiated. Figure 4 indicates H&E staining of
tumor tissues from studied animals. These results revealed
no major differences in the sizes and the histology of the
tumors (P > 0.05).
Immunohistochemistry
Immunohistochemical analysis was conducted using Ki-
67 and CD34 antibodies. Immunoreactive SW-48 cells
to anti- Ki-67 are brown nuclear with a diffuse pattern.
It was scored by counting about 1000 cells in 10 differ-
ent fields. Each brown stained nucleus was considered
positive, regardless of intensity (Figure 5). Immunohisto-
chemical staining of treated and untreated nude mice’s-48 cells. SW-48 cells were treated by 0.5, 1 and 2 μM for 48 h. Cell
. A: MTT assay of SW-48 cells after treatment with SD-208 in comparison
s after treatment with SD-208 comparison with controls (untreated and
arison with the controls, which were arbitrarily assigned 100% cell
eration of SW-48 cells in different concentrations of SD-208 to control.
the mean ± SEM from three independent experiments.
Figure 3 A representative of colorectal adenocarcinoma model. Tumor implantation; athymic nude mice implanted by SW-48 cell line, the
cells were grown as tumor xenografts after 10 days. Cancer-bearing nude mice were treated with 50 mg/kg/day of SD-208 (A) or without
SD-208 (B).
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showed no significant changes among studied samples.
Ki-67 and CD34 expressions in the tumor xenografts
The results from the immunochemical assay indicated
that Ki-67 was predominantly expressed in the nucleus.
As already pointed out, the immunohistochemically
stained tumors with anti-Ki-67 showed positively brown
nuclear in the studied tissues (Figure 5). The Ki-67 ex-
pression levels between the test and control groups did
not show significant changes (P > 0.05). Immunohisto-
chemical staining using anti-CD34 antibody on tumor
tissues from either treated or untreated nude mice with
SD-208 showed cytoplasmic membrane of endothelial
cells in brown color and marked microvessels prolifera-
tion (Figure 6).
Discussion
Despite aggressive surgery, radiotherapy and chemother-
apy, treatment of malignant CRC remains formidable. Even
though that TGF-β suppresses proliferation of certain car-
cinoma cells and is well-known to be a tumor suppressor,Figure 4 A representative results of pathological examinations
of nude mice tumors with or without SD-208 treatment. A:
tumors of nude mice treated with 50 mg/kg/day stained with H&E.
B: H&E staining of tumor tissues of control. No significant difference
histologically was observed (P > 0.05).it promotes tumor development, progression and metas-
tasis in human cancers including CRC, glioma, osteosar-
coma, breast, lung and pancreatic cancers [14-16]. The
insights into the role of the TGF-β signaling in carcinogen-
esis importantly have come due to experimental study on
animal models. Understanding the mechanisms by which
TGF-β signaling regulates tumor development and pro-
gression is critical for designing the beneficial therapeutic
strategies for the cancers [14,16-18]. In the last few years,
because of availability and easily drug delivery, the tar-
geting of receptor kinases by small-molecule inhibitors
has been a profound area of experimental cancer stud-
ies [16,17,19].
It is thought that pharmacological blockade of the
TGF-β signaling pathway by TGβRI inhibitors may be as
a potential strategy for cancer therapy [17-19]. For the
first time, we evaluated the efficacy of systemic targeting
of the TGF-β pathway by a TGβRI kinase inhibitor, SD-
208, on a high-grade colon adenocarcinoma cell line,
SW-48, in vitro and in developed heterotopic colon tu-
mors in model that shares similarities with human colon
cancer. Our findings using MTT and BrdU assays dem-
onstrated that treatment of SW-48 cells with SD-208
using different doses had no significant inhibitory effects
on cell growth and proliferation. Our in vitro results
were consistent with one study revealing SD-208 can
not reduce viability or proliferation of human malignant
glioma cells [17]. However, this study showed that SD-
208 regulates the growth of glioma in syngeneic mice
without changes in proliferation, apoptosis or angiogen-
esis. Also, other investigators demonstrated that SD-208
failed to inhibit R3T tumor growth or metastasis in athy-
mic nude mice [20]. On the other hand, some studies
suggested that the various kinase inhibitors including
SD-208, were able to inhibit TGF-β-evoked migration
and invasion [20-22]. These results indicated that re-
duction of tumors was due to regulation of immune
Figure 5 Colon adenocarcinoma (grade IV) stained
immunohistochemically with anti-Ki-67. Positive immunoreactive
showing brown nuclear expression of Ki-67 with a large number
(~80%) of stained nuclei reflecting active cellular proliferation in the
treated nude mice with SD-208 (A) and control (B): Immunohischemical
assay showed no significant difference between tests and controls in
terms of cellular proliferation (P > 0.05).
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reactive immune regulation and increased immune infil-
tration [21,22]. Thereby, it has been commented that
SD-208 could be a promising agent for the treatment of
human malignancy and other conditions associated with
pathological TGF-β activity.
In addition, we revealed that when drinking water con-
tains SD-208 daily, the drug could not inhibit the growth
of established heterotopic SW-48 tumors and its progres-
sion in nude mice. Further histological analysis indicated
that SD-208 had no significant effects on proliferation
(Ki-67 positivity) or the number of blood vessels and
angiogenesis (CD34 positivity). This is consistent with re-
ports by others showing SD-208 had no effect on the
growth of primary and metastatic R3T mammary tumors
in athymic nude mice [18]. In the agreement with our
results and previous studies, it has been shown that an
inhibitor of TGF-β receptor 1 kinase, SM16, lost efficacy
against the AB12 mesothelioma model in SCID mice [21].Figure 6 Colon adenocarcinoma (grade IV) stained immunohistochem
tissues were stained with anti-CD34 antibody and positive immunoreactive
marked microvessel's proliferation. Microvessel density (MVD) was ~40 m
no significant immunohistologically differences (P > 0.05). Note the prom
membrane.Also, we found that SD-208 is not effective in limiting
heterotopic tumor growth and not proper to treat estab-
lished primary tumors settings at least in SW-48 colorectal
cancer cells. The failure of SD-208 to inhibit SW-48 tumor
growth in nude mice suggests that the suppression of
angiogenesis and proliferation could be dependent on cell
lineage and cell context [23]. Our results are not the first
report suggesting the inability of SD-208 to inhibit angio-
genesis and proliferation. Some researchers reported that
SD-208 was unable to cause differences in microvessel
density in gliomas [17]. Furthermore, a study of two TGF-
βR1 inhibitors, SD-093 and SD-208, on two murine mam-
mary carcinoma cell lines (R3T and 4 T1) revealed that
SD-208 failed to inhibit R3T tumor growth or metastasis
in athymic nude mice. However, SD-208 treatment led to a
reduction in microvessel density in mammary tumors [20].
It is quite understandable that the efficacy of this kin-
ase inhibitor is a controversial issue in cancer treatment
[20]. In this regard, several scenarios could be proposed
to elucidate the failure of SD-208 as an anti-tumor: (1)
genetic alterations such as chromosomal abnormalities
and (2) gene mutation in any TGF-β signaling pathway.
Conclusion
We have demonstrated that SD-208, a TGβRI kinase inhibi-
tor, was not able to reduce tumor growth and angiogenesis
in a heterotopic human colorectal cancer model. Our re-
sults also for the first time indicated that this anti-cancer
agent could not potentially have a therapeutic benefit in at
least proportion of CRC. To get more insight into the po-
tential biological effects of SD-208 on CRC, different CRC
cells with various differentiated status are required to treat
with SD-208. Moreover, because of the complexity of TGF-
β signaling role and crosstalk with other factors (such as
immunochemotactic and angiogenic agents) in the derivedically with anti-CD34. The paraffin embedded sections of tumor
indicating brown cytoplasmic membrane of endothelial cells and
icrovessel/mm2. SD-208-treated tumors (A) vs controls (B) revealed
inent vascularity. Arrows indicate CD34 staining of the cytoplasmic
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tion strategies for targeting tumors in this field, should be
very carefully.
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